Close Menu

phase I clinical study

The two companies will evaluate the efficacy of the combination in patients with ER-positive, HER2-negative, advanced breast cancer.

Chi-Med subsidiary Hutchison Medipharma has kicked off the Phase I trial in China and has dosed its first patient with the investigational IDH inhibitor.

The study will assess the maximum tolerated dose of the first-in-class drug, QBS10072S, for patients with a variety of metastatic cancers expressing LAT1 signatures.

The drug, designed to reactivate p53, will be evaluated in combination with chemotherapy and Venclexta as a frontline treatment for patients with TP53-mutant AML.

The Phase Ib/II trial will assess dosage and antitumor activity of MEN1611 plus Erbitux for patients with PIK3CA-mutated, RAS and RAF wildtype advanced colorectal cancer.

Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.

The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.

More than 40 percent of women with advanced mismatch repair-deficient endometrial cancer had an objective response to GSK's anti-PD-1 monoclonal antibody.

Preclinical studies showed that combining CUE-101 with an anti-PD1 checkpoint inhibitor could increase anti-tumor efficacy in advanced HPV-positive head and neck tumors.

Affimed announced the first patient dosed in a Phase I/IIb trial of AFM24, designed to bind CD16A receptors on innate immune cells and EGFR receptors on tumor cells.